Pittenger & Anderson Inc. Has $15.57 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Pittenger & Anderson Inc. raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 25,167 shares of the medical research company’s stock after buying an additional 304 shares during the quarter. Pittenger & Anderson Inc.’s holdings in Thermo Fisher Scientific were worth $15,568,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. United Community Bank grew its position in Thermo Fisher Scientific by 14.0% in the first quarter. United Community Bank now owns 203 shares of the medical research company’s stock valued at $118,000 after acquiring an additional 25 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S increased its position in Thermo Fisher Scientific by 24.2% during the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 11,480 shares of the medical research company’s stock worth $6,672,000 after purchasing an additional 2,234 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in Thermo Fisher Scientific in the first quarter valued at approximately $251,000. Callan Capital LLC bought a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at $287,000. Finally, TFB Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at $245,000. Institutional investors own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the transaction, the senior vice president now directly owns 12,736 shares of the company’s stock, valued at approximately $7,134,197.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the sale, the executive vice president now directly owns 16,663 shares of the company’s stock, valued at approximately $9,333,946.08. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the transaction, the senior vice president now directly owns 12,736 shares in the company, valued at $7,134,197.76. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 18,150 shares of company stock valued at $10,094,925. 0.34% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of recent research reports. Bank of America upped their target price on Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a “buy” rating in a report on Monday, September 16th. Bernstein Bank raised their price objective on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a report on Tuesday, October 22nd. Barclays reduced their target price on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. JPMorgan Chase & Co. lifted their price target on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an “overweight” rating in a report on Friday, September 20th. Finally, Morgan Stanley increased their price objective on Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a report on Friday, September 20th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $649.33.

Thermo Fisher Scientific Trading Down 0.4 %

NYSE:TMO opened at $555.47 on Tuesday. The firm has a fifty day simple moving average of $598.39 and a two-hundred day simple moving average of $583.86. Thermo Fisher Scientific Inc. has a 12 month low of $437.26 and a 12 month high of $627.88. The stock has a market capitalization of $212.19 billion, a price-to-earnings ratio of 34.83, a PEG ratio of 3.69 and a beta of 0.79. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. During the same period in the prior year, the business earned $5.69 EPS. The firm’s revenue for the quarter was up .2% on a year-over-year basis. Analysts expect that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current fiscal year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.